|
1
|
Sturgeon CM, Duffy MJ, Stenman UH, Lilja
H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ,
et al: National academy of clinical biochemistry laboratory
medicine practice guidelines for use of tumor markers in
testicular, prostate, colorectal, breast, and ovarian cancers. Clin
Chem. 54:e11–e79. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Duffy MJ: Biochemical markers in breast
cancer: Which ones are clinically useful? Clin Biochem. 34:347–352.
2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Duffy MJ: Predictive markers in breast and
other cancers: A review. Clin Chem. 51:494–503. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Duffy MJ, Walsh S, McDermott EW and Crown
J: Biomarkers in breast cancer: Where Are we and where are we
going? Adv Clin Chem. 71:1–23. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Duffy MJ, Evoy D and McDermott EW: CA
15-3: Uses and limitation as a biomarker for breast cancer. Clin
Chim Acta. 411:1869–1874. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Silver RM: Clinical aspects of systemic
sclerosis (scleroderma). Ann Rheum Dis. 50 (Suppl 4):S854–S861.
1991.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Varga J and Abraham D: Systemic sclerosis:
A prototypic multisystem fibrotic disorder. J Clin Invest.
117:557–567. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Wells AU, Steen V and Valentini G:
Pulmonary complications: One of the most challenging complications
of systemic sclerosis. Rheumatology (Oxford). 48 (Suppl
3):iii40–iii44. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Steen VD and Medsger TA: Changes in causes
of death in systemic sclerosis, 1972-2002. Ann Rheum Dis.
66:940–944. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Prasse A and Müller-Quernheim J:
Non-invasive biomarkers in pulmonary fibrosis. Respirology.
14:788–795. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ishikawa N, Hattori N, Yokoyama A and
Kohno N: Utility of KL-6/MUC1 in the clinical management of
interstitial lung diseases. Respir Investig. 50:3–13.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kohno N, Akiyama M, Kyoizumi S, Hakoda M,
Kobuke K and Yamakido M: Detection of soluble tumor-associated
antigens in sera and effusions using novel monoclonal antibodies,
KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol.
18:203–216. 1988.PubMed/NCBI
|
|
13
|
Tanaka S, Hattori N, Ishikawa N, Shoda H,
Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, et al:
Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients
with surgically resected nonsmall cell lung cancer. Int J Cancer.
130:377–387. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yamasaki H, Ikeda S, Okajima M, Miura Y,
Asahara T, Kohno N and Shimamoto F: Expression and localization of
MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic
tumors. Int J Oncol. 24:107–113. 2004.PubMed/NCBI
|
|
15
|
Ricci A, Mariotta S, Bronzetti E, Bruno P,
Vismara L, De Dominicis C, Laganà B, Paone G, Mura M, Rogliani P,
et al: Serum CA 15-3 is increased in pulmonary fibrosis.
Sarcoidosis Vasc Diffuse Lung Dis. 26:54–63. 2009.PubMed/NCBI
|
|
16
|
Valerio Marzano A, Morabito A, Berti E and
Caputo R: Elevated circulating CA 15.3 levels in a subset of
systemic sclerosis with severe lung involvement. Arch Dermatol.
134(645)1998.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Celeste S, Santaniello A, Caronni M,
Franchi J, Severino A, Scorza R and Beretta L: Carbohydrate antigen
15.3 as a serum biomarker of interstitial lung disease in systemic
sclerosis patients. Eur J Intern Med. 24:671–676. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Greene FL: Breast tumours. In: TNM
classification of malignant tumours. Sobin LH, Gospodarowicz MK and
Wittekind C (eds). 7th edition. Wiley-Blackwell, Oxford, pp181-193,
2009.
|
|
19
|
Hackshaw MD, Danysh HE, Singh J, Ritchey
ME, Ladner A, Taitt C, Camidge DR, Iwata H and Powell CA: Incidence
of pneumonitis/interstitial lung disease induced by HER2-targeting
therapy for HER2-positive metastatic breast cancer. Breast Cancer
Res Treat. 183:23–39. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Varga J: Systemic sclerosis: An update.
Bull NYU Hosp Jt Dis. 66:198–202. 2008.PubMed/NCBI
|
|
21
|
Tyndall AJ, Bannert B, Vonk M, Airò P,
Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U,
Distler O, et al: Causes and risk factors for death in systemic
sclerosis: A study from the EULAR scleroderma trials and research
(EUSTAR) database. Ann Rheum Dis. 69:1809–1815. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Volkmann ER and Fischer A: Update on
morbidity and mortality in systemic sclerosis-related interstitial
lung disease. J Scleroderma Relat Disord. 6:11–20. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rubio-Rivas M, Royo C, Simeón CP, Corbella
X and Fonollosa V: Mortality and survival in systemic sclerosis:
Systematic review and meta-analysis. Semin Arthritis Rheum.
44:208–219. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Steen VD, Conte C, Owens GR and Medsger TA
Jr: Severe restrictive lung disease in systemic sclerosis.
Arthritis Rheum. 37:1283–1289. 1994.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tashkin DP, Elashoff R, Clements PJ,
Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C,
Bolster M, et al: Cyclophosphamide versus placebo in scleroderma
lung disease. N Engl J Med. 354:2655–2666. 2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tashkin DP, Roth MD, Clements PJ, Furst
DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja
S, et al: Mycophenolate mofetil versus oral cyclophosphamide in
scleroderma-related interstitial lung disease (SLS II): A
randomised controlled, double-blind, parallel group trial. Lancet
Respir Med. 4:708–719. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Colaci M, Giuggioli D, Vacchi C, Lumetti
F, Iachetta F, Marcheselli L, Federico M and Ferri C: Breast cancer
in systemic sclerosis: Results of a cross-linkage of an Italian
rheumatologic center and a population-based cancer registry and
review of the literature. Autoimmun Rev. 13:132–137.
2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Abu-Shakra M, Guillemin F and Lee P:
Cancer in systemic sclerosis. Arthritis Rheum. 36:460–464.
1993.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Szekanecz É, Szamosi S, Horváth Á, Németh
Á, Juhász B, Szántó J, Szücs G and Szekanecz Z: Malignancies
associated with systemic sclerosis. Autoimmun Rev. 11:852–855.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Scope A, Sadetzki S, Sidi Y, Barzilai A,
Trau H, Kaufman B, Catane R and Ehrenfeld M: Breast cancer and
scleroderma. Skinmed. 5:18–24. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hill CL, Nguyen AM, Roder D and
Roberts-Thomson P: Risk of cancer in patients with scleroderma: A
population based cohort study. Ann Rheum Dis. 62:728–731.
2003.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Maria ATJ, Partouche L, Goulabchand R,
Rivière S, Rozier P, Bourgier C, Le Quellec A, Morel J, Noël D and
Guilpain P: Intriguing relationships between cancer and systemic
sclerosis: Role of the immune system and other contributors. Front
Immunol. 9(3112)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Straub RH, Zeuner M, Lock G, Schölmerich J
and Lang B: High prolactin and low dehydroepiandrosterone sulphate
serum levels in patients with severe systemic sclerosis. Br J
Rheumatol. 36:426–432. 1997.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang M, Wu X, Chai F, Zhang Y and Jiang J:
Plasma prolactin and breast cancer risk: A meta-analysis. Sci Rep.
6(25998)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li CI, Daling JR, Tang MT, Haugen KL,
Porter PL and Malone KE: Use of antihypertensive medications and
breast cancer risk among women aged 55 to 74 years. JAMA Intern
Med. 173:1629–1637. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gómez-Acebo I, Dierssen-Sotos T,
Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, Alonso MH, Moreno
V, Amiano P, Molina de la Torre AJ, et al: The use of
antihypertensive medication and the risk of breast cancer in a
case-control study in a spanish population: The MCC-spain study.
PLoS One. 11(e0159672)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bernal-Bello D, García de Tena J,
Simeón-Aznar C and Fonollosa-Pla V: Systemic sclerosis, breast
cancer and calcium channel blockers: A new player on the scene?
Autoimmun Rev. 13:880–881. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Brasky TM, Krok-Schoen JL, Liu J,
Chlebowski RT, Freudenheim JL, Lavasani S, Margolis KL, Qi L,
Reding KW, Shields PG, et al: Use of calcium channel blockers and
breast cancer risk in the women's health initiative. Cancer
Epidemiol Biomarkers Prev. 26:1345–1348. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Baltus JA, Boersma JW, Hartman AP and
Vandenbroucke JP: The occurrence of malignancies in patients with
rheumatoid arthritis treated with cyclophosphamide: A controlled
retrospective follow-up. Ann Rheum Dis. 42:368–373. 1983.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gulamhusein A and Pope JE: Squamous cell
carcinomas in 2 patients with diffuse scleroderma treated with
mycophenolate mofetil. J Rheumatol. 36:460–462. 2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Okada K, Endo Y, Miyachi Y, Koike Y,
Kuwatsuka Y and Utani A: Glycosaminoglycan and versican deposits in
taxane-induced sclerosis. Br J Dermatol. 173:1054–1058.
2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hung CH, Chan SH, Chu PM and Tsai KL:
Docetaxel facilitates endothelial dysfunction through oxidative
stress via modulation of protein kinase C beta: The protective
effects of sotrastaurin. Toxicol Sci. 145:59–67. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Abu-Shakra M and Lee P: Exaggerated
fibrosis in patients with systemic sclerosis (scleroderma)
following radiation therapy. J Rheumatol. 20:1601–1603.
1993.PubMed/NCBI
|
|
44
|
Darras-Joly C, Wechsler B, Blétry O and
Piette JC: De novo systemic sclerosis after radiotherapy: A report
of 3 cases. J Rheumatol. 26:2265–2267. 1999.PubMed/NCBI
|
|
45
|
Shah DJ, Hirpara R, Poelman CL, Woods A,
Hummers LK, Wigley FM, Wright JL, Parekh A, Steen VD, Domsic RT and
Shah AA: Impact of radiation therapy on scleroderma and cancer
outcomes in scleroderma patients with breast cancer. Arthritis Care
Res (Hoboken). 70:1517–1524. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Verhulst L, Noë E, Morren MA, Verslype C,
Van Cutsem E, Van den Oord JJ and De Haes P: Scleroderma-like
cutaneous lesions during treatment with paclitaxel and gemcitabine
in a patient with pancreatic adenocarcinoma. Review of literature.
Int J Dermatol. 57:1075–1079. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Itoh M, Yanaba K, Kobayashi T and Nakagawa
H: Taxane-induced scleroderma. Br J Dermatol. 156:363–367.
2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Sokołowska-Wojdyło M, Kłudkowska J,
Olszewska B, Seredyńska J, Biernat W, Błażewicz I,
Rustowska-Rogowska A and Nowicki RJ: The first case of drug-induced
pseudoscleroderma and eczema craquelé related to nab-paclitaxel
pancreatic adenocarcinoma treatment. Postepy Dermatol Alergol.
35:106–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shibao K, Okiyama N, Maruyama H, Jun-Ichi
F and Fujimoto M: Scleroderma-like skin changes occurring after the
use of paclitaxel without any chemical solvents: A first case
report. Eur J Dermatol. 26:317–318. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Battafarano DF, Zimmerman GC, Older SA,
Keeling JH and Burris HA: Docetaxel (Taxotere) associated
scleroderma-like changes of the lower extremities. A report of
three cases. Cancer. 76:110–115. 1995.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hamaguchi Y: Autoantibody profiles in
systemic sclerosis: Predictive value for clinical evaluation and
prognosis. J Dermatol. 37:42–53. 2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kufe D, Inghirami G, Abe M, Hayes D,
Justi-Wheeler H and Schlom J: Differential reactivity of a novel
monoclonal antibody (DF3) with human malignant versus benign breast
tumors. Hybridoma. 3:223–232. 1984.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wakamatsu K, Nagata N, Kumazoe H, Oda K,
Ishimoto H, Yoshimi M, Takata S, Hamada M, Koreeda Y, Takakura K,
et al: Prognostic value of serial serum KL-6 measurements in
patients with idiopathic pulmonary fibrosis. Respir Investig.
55:16–23. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Baldus SE, Engelmann K and Hanisch FG:
MUC1 and the MUCs: A family of human mucins with impact in cancer
biology. Crit Rev Clin Lab Sci. 41:189–231. 2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Kruit A, Gerritsen WB, Pot N, Grutters JC,
van den Bosch JM and Ruven HJ: CA 15-3 as an alternative marker for
KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis.
27:138–146. 2010.PubMed/NCBI
|
|
56
|
Uehara M, Kinoshita T, Hojo T,
Akashi-Tanaka S, Iwamoto E and Fukutomi T: Long-term prognostic
study of carcinoembryonic antigen (CEA) and carbohydrate antigen
15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 13:447–451.
2008.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shering SG, Sherry F, McDermott EW,
O'Higgins NJ and Duffy MJ: Preoperative CA 15-3 concentrations
predict outcome of patients with breast carcinoma. Cancer.
83:2521–2527. 1998.PubMed/NCBI
|
|
58
|
Shao Y, Sun X, He Y, Liu C and Liu H:
Elevated levels of serum tumor markers CEA and CA15-3 are
prognostic parameters for different molecular subtypes of breast
cancer. PLoS One. 10(e0133830)2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Fu Y and Li H: Assessing clinical
significance of serum CA15-3 and carcinoembryonic antigen (CEA)
levels in breast cancer patients: A meta-analysis. Med Sci Monit.
22:3154–3162. 2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Di Gioia D, Dresse M, Mayr D, Nagel D,
Heinemann V and Stieber P: Serum HER2 in combination with CA 15-3
as a parameter for prognosis in patients with early breast cancer.
Clin Chim Acta. 440:16–22. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wojtacki J, Kruszewski WJ, Sliwińska M,
Kruszewska E, Hajdukiewicz W, Sliwiński W, Rolka-Stempniewicz G,
Góralczyk M and Leśniewski-Kmak K: Elevation of serum Ca 15-3
antigen: An early indicator of distant metastasis from breast
cancer. Retrospective analysis of 733 cases. Przegl Lek.
58:498–503. 2001.PubMed/NCBI(In Polish).
|
|
62
|
Tampellini M, Berruti A, Bitossi R,
Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG,
Manzin E, et al: Prognostic significance of changes in CA 15-3
serum levels during chemotherapy in metastatic breast cancer
patients. Breast Cancer Res Treat. 98:241–248. 2006.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Chourin S, Veyret C, Chevrier A, Loeb A,
Gray C and Basuyau J: Routine use of serial plasmatic CA 15-3
determinations during the follow-up of patients treated for breast
cancer. Evaluation as factor of early diagnosis of recurrence. Ann
Biol Clin (Paris). 66:385–392. 2008.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
64
|
Yang Y, Zhang H, Zhang M, Meng Q, Cai L
and Zhang Q: Elevation of serum CEA and CA15-3 levels during
antitumor therapy predicts poor therapeutic response in advanced
breast cancer patients. Oncol Lett. 14:7549–7556. 2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Kim HS, Park YH, Park MJ, Chang MH, Jun
HJ, Kim KH, Ahn JS, Kang WK, Park K and Im YH: Clinical
significance of a serum CA15-3 surge and the usefulness of CA15-3
kinetics in monitoring chemotherapy response in patients with
metastatic breast cancer. Breast Cancer Res Treat. 118:89–97.
2009.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Wong RC, Brown S, Clarke BE, Klingberg S
and Zimmerman PV: Transient elevation of the tumor markers CA 15-3
and CASA as markers of interstitial lung disease rather than
underlying malignancy in dermatomyositis sine myositis. J Clin
Rheumatol. 8:204–207. 2002.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Inagaki Y, Xu H, Nakata M, Seyama Y,
Hasegawa K, Sugawara Y, Tang W and Kokudo N: Clinicopathology of
sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal,
hepatic and pancreatic cancers. Biosci Trends. 3:220–232.
2009.PubMed/NCBI
|
|
68
|
Szekanecz E, Szucs G, Szekanecz Z, Tarr T,
Antal-Szalmás P, Szamosi S, Szántó J and Kiss E: Tumor-associated
antigens in systemic sclerosis and systemic lupus erythematosus:
Associations with organ manifestations, immunolaboratory markers
and disease activity indices. J Autoimmun. 31:372–376.
2008.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Ogawa Y, Ishikawa T, Ikeda K, Nakata B,
Sawada T, Ogisawa K, Kato Y and Hirakawa K: Evaluation of serum
KL-6, a mucin-like glycoprotein, as a tumor marker for breast
cancer. Clin Cancer Res. 6:4069–4072. 2000.PubMed/NCBI
|
|
70
|
Kohno N: Serum marker KL-6/MUC1 for the
diagnosis and management of interstitial pneumonitis. J Med Invest.
46:151–158. 1999.PubMed/NCBI
|
